FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to molecular and experimental oncology and represents a pharmaceutical combination for simultaneous, separate or consecutive introduction which contains substrata phosphorylation site inhibitor CK2 which includes peptide P15 (CWMSPRHLGTC) together with a cytostatic agent pharmaceutically acceptably mixed with the appropriate carriers.
EFFECT: invention provides higher therapeutic index of current cytotoxic agent, by reducing an effective dose and natural toxicity exhibited by the medicines of such type, and evasion of chemical stability of a tumour with respect to conventional cytotoxic agents.
12 cl, 4 ex, 4 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOMODULATORY AND ANTINEOPLASTIC PEPTIDES | 2007 |
|
RU2430109C2 |
| PEPTIDE POSSESSING CAPACITY TO BIND CASEIN KINASE II (CKII) PHOSPHORYLATING SITE AND TO INHIBIT PHOSPHORYLATION, FUSED POLYPEPTIDE, THEIR USING | 2002 |
|
RU2290410C2 |
| ACTIVE ANGIOGENESIS-PREVENTING IMMUNETHERAPY | 2003 |
|
RU2329824C2 |
| CYCLIC PEPTIDES WITH ANTINEOPLASTIC AND ANTIANGIOGENIC ACTIVITY | 2012 |
|
RU2603286C2 |
| METHOD FOR THERAPY OF MALIGNANT TUMOUR | 2011 |
|
RU2577993C2 |
| SYNERGIC COMBINATION OF PROTEASOME INHIBITOR AND VITAMIN K FOR INHIBITION OF GROWTH AND PROLIFERATION OF TUMOUR CELLS, PHARMACEUTICAL COMPOSITION AND THEREOF-BASED ANTI-TUMOUR MEDICATION | 2013 |
|
RU2563986C2 |
| ANTICANCER TUMOR CISPLATIN COMPOSITION WITH 6-PHOSPHOGLUCONATE DEHYDROGENASE INHIBITOR | 2019 |
|
RU2693004C1 |
| ANTI-TUMOUR PREPARATION | 2011 |
|
RU2451509C1 |
| HIGHLY EFFECTIVE METHOD FOR PREPARING DOSAGE FORM OF TARGETED ACTION FOR THERAPY OF MALIGNANT GROWTHS | 2019 |
|
RU2727924C1 |
| ANTICANCER PHARMACEUTICAL COMPOSITION (VERSIONS) AND APPLICATION THEREOF | 2005 |
|
RU2396274C2 |
